Ubiquigent and Debiopharm Enter Agreement to Support USP1 Inhibitor Programme for Debio 0432

Project will be a demonstration of how Ubiquigent’s DUB-centric platform can support the development of DUB inhibitors all the way from discovery through to clinical development.

DUNDEE, Scotland & LAUSANNE, Switzerland--(BUSINESS WIRE)-- Ubiquigent Limited (Ubiquigent), a drug discovery and development company harnessing novel deubiquitinase (DUB) modulators as new therapeutics for areas of high unmet medical need, today announced an agreement with Debiopharm, a biopharmaceutical company aiming to develop tomorrow’s standard-of-care treatments to cure cancer and infectious diseases. The agreement will support the development of Debiopharm’s USP1 inhibitor programme, Debio 0432.

Under the terms of the agreement, Ubiquigent will deploy its DUB-focused platform, combined with its deep understanding of the DUB field, to develop novel target engagement assays to support Debio-0432 as it approaches the clinic.

Currently, in late-stage preclinical development, Debio 0432 is a small molecule with best-in-class potential that could be deployed to combat multiple tumour types. Through its potent and selective inhibition of USP1, a critical player in the DNA damage repair (DDR) pathway, Debio 0432 has the potential to induce synthetic lethality in tumour types with underlying defects of DNA repair genes.

“We are delighted to enter this agreement with Debiopharm, supporting the development of its advanced USP1 inhibitor programme. Following our successful collaborations with other clinical stage companies, this latest agreement further demonstrates the capability of Ubiquigent’s platform to address all aspects of DUB drug discovery and development, encompassing target validation, hit-to-lead, candidate selection, translational research, and the development of assays to support clinical evaluation.” Jason Mundin, CEO of Ubiquigent, said: “With multiple assets now reaching clinical stage, we look forward to seeing the continued progression and expansion of the DUB field over the coming years as more companies enter the space and new therapeutics enter the clinic.”

Bertrand Ducrey, CEO, Debiopharm, commented: “Ubiquigent’s specialised drug discovery platform is uniquely positioned to support our USP1 inhibitor programme as it approaches the clinic, enabling the development of novel target engagement assays. Selective inhibition of USP1 to interrupt DNA damage repair pathway is an exciting approach to cancer treatment.”

To learn more about Ubiquigent’s platform for DUB-focused drug discovery, visit: https://www.ubiquigent.com/platform

View source version on businesswire.com: https://www.businesswire.com/news/home/20240326540510/en/

Contacts

Esmé Walters
Zyme Communications
E-mail: esme.walters@zymecommunications.com
Phone: +44 (0) 7377 543244

Source: Ubiquigent

Powered by Business Wire

View this news release online at:
http://www.businesswire.com/news/home/20240326540510/en

Back to news